REDI-DxTM (Radiation Exposure Dosage Index) is a test designed to provide an estimate of individualized levels of absorbed radiation exposure (biodosimetry) following a nuclear incident. REDI-Dx provides quantitative assessment of multiple biomarkers from a drop of blood.


DxTerity is developing a "from home" monitoring test that is designed to provide accurate assessment of stable disease status and potentially warn of impending flares before they manifest for the 1.5 million patients suffering from Rhuematoid Arthritis.


DxTerity Diagnostics Announces CLIA Licensure of its Clinical Testing Laboratory

REDI-Dx Wins 2013 NCT CBRNe Product of the Year Award

Performance of DxTerity's Radiation Exposure Test Demonstrated in NATO Study

PCR Insider: DxTerity Developing Radiation Toxicity Prediction Assay

DxTerity Wins Contract to Develop a Test for Predicting Radiation Toxicity

DxTerity Completes Fingerstick Sample Collection Study for REDI-Dx

DxTerity Open New 10,000 Square Foot Molecular Testing Lab

DxTerity Announce Launch of REDI-Dx Biodosimetry Assay at IRPA 2012 Meeting (Glasgow)

DxTerity Wins SBIR Grant for Development of One-Step FFPE Gene Expression Solution

DxTerity Acquires Gene Signature Portfolio from SourceMDx